Oncolytic Viruses and Novel Biologic Therapies

Oncolytic viruses are engineered or naturally occurring viruses that selectively infect and kill cancer cells while sparing normal tissue. They stimulate antitumor immune responses and can be combined with immunotherapy for enhanced efficacy. Talimogene laherparepvec (T-VEC) is an FDA-approved oncolytic virus for melanoma. Novel biologic therapies also include monoclonal antibodies, bispecific T-cell engagers, and fusion proteins, which harness the immune system to recognize and attack tumors. These therapies represent a shift toward precision immunotherapy, offering new hope for hard-to-treat cancers. Ongoing trials aim to refine delivery, enhance tumor specificity, and minimize immune-related side effects.

    Related Conference of Oncolytic Viruses and Novel Biologic Therapies

    February 05-06, 2026

    11th World Conference on Breast and Cervical Cancer

    Paris, France
    February 19-20, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    February 19-20, 2026

    8th International Conference on Women Oncology

    Miami, USA
    March 09-10, 2026

    4th World Congress on Oral Cancer

    Singapore City, Singapore
    March 30-31, 2026

    26th World Congress on Cancer and Diagnostics

    London, UK
    June 15-16, 2026

    10th Global Meeting on Oncology and Radiology

    Paris, France
    June 22-23, 2026

    16th World Congress on Breast Cancer

    Dubai, UAE
    June 23-24, 2026

    27th World Congress on Cancer Summit

    Paris, France
    July 27-28, 2026

    6th World Congress on Breast Cancer

    Rome, Italy
    September 28-29, 2026

    36th Experts Meet On Cancer Research & Therapy

    Aix-en-Provence, France

    Oncolytic Viruses and Novel Biologic Therapies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in